Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Enzon Will Spin Off Biotech Business

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

Specialty drug manufacturer Enzon Pharmaceuticals will spin off its biotechnology division, which specializes in PEGylation and nucleic acid technology for drug discovery. The deal will result in two independent public companies. Enzon expects to fund the new company with $150 million in cash. Enzon will retain its current products on the market, its Indianapolis manufacturing facility, and royalties from licensing of PEGylation technology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.